...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart? injection device
【24h】

An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart? injection device

机译：对英国和爱尔兰的患者使用RebiSmart对皮下干扰素β-1a注射的依从性进行观察性回顾性审计。注射装置

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Poor adherence to disease-modifying drugs is associated with an increased risk of relapse in patients with multiple sclerosis. However, adherence is difficult to assess objectively. RebiSmart? (Merck Serono SA, Geneva, Switzerland), a device for subcutaneous (sc) injection of interferon (IFN) β-1a, features an electronic injection log that can assist in objective monitoring of adherence.Objective: To assess adherence to sc IFN β-1a injections using data from RebiSmart?.Methods: This was a single-group, observational, retrospective audit. Adherence data were collected from patients with relapsing multiple sclerosis in the United Kingdom and Ireland who had been prescribed sc IFN β-1a and had been using RebiSmart? for a minimum of 24 months.Results: In total, 225 patients were included in the full analysis set; 72% were in the United Kingdom, and 28% were in Ireland. Overall, the mean age was 44.1 years, and 73% were women. Patients received sc IFN β-1a 44 μg (68%) or 22 μg (32%) three times per week. Mean adherence over the course of 24 months was 95.0% (median, 99.4%), and similar values were observed across all periods. The proportion of patients with 80% or higher adherence was 92.0% at 12 months and 91.1% at 24 months.Conclusion: High adherence to sc IFN β-1a was observed across all patient groups using RebiSmart?, according to 2-year treatment adherence data. This may be partly attributed to the expert support patients received, supplemented by routine and regular contact from the MySupport patient-support program, as well as the self-motivation of patients who persisted with treatment for 2 or more years.
机译：背景：对疾病改变药物的依从性差与多发性硬化症患者复发风险增加有关。但是，依从性很难进行客观评估。 RebiSmart？ （Merck Serono SA，日内瓦，瑞士），用于皮下（sc）注射干扰素（IFN）β-1a的装置，具有电子注射记录，可以帮助客观监测依从性。目的：评估对sc IFNβ的依从性。使用RebiSmart？的数据进行-1a注射。方法：这是单组，观察性，回顾性审核。依从性数据来自英国和爱尔兰的复发性多发性硬化症患者，这些患者已开具sc IFNβ-1a处方并一直使用RebiSmart？结果：至少有24个月。结果：完整的分析集中总共包括225名患者;英国有72％，爱尔兰有28％。总体而言，平均年龄为44.1岁，其中73％为女性。患者每周三次接受44μg（68％）或22μg（32％）sc IFNβ-1a。在24个月的过程中，平均依从性为95.0％（中位数为99.4％），并且在所有期间均观察到相似的值。坚持治疗80％或更高的患者比例在12个月时为92.0％，在24个月时为91.1％。结论：根据2年治疗依从性，在所有使用RebiSmart？的患者组中均观察到对sc IFNβ-1a的高度依从数据。这可能部分归因于获得了专家支持的患者，再加上MySupport患者支持计划的常规和定期联系，以及坚持治疗2年以上的患者的自我激励。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号